Friday, March 01, 2024
name of Prensa Latina
Bandera inglesa
English Edition
name of Prensa Latina

NEWS

NEWS

Brazilian pharmaceutical company visits Cuba’s research center

Havana, Apr 27 (Prensa Latina) A Brazilian company MRJ Farma´s representation on Thursday paid a visit to Cuba´s Center for Genetic Engineering and Biotechnology (CIGB) South American specialists were detailed about CIGB´s scientific breakthroughs.

A Brazilian delegation visited CIGB and learned about our products and innovative projects, as posted by CIGB on Twitter.

Founded in 1986 by Fidel Castro, the CIGB imprints its name in the scientific history of Cuba and the world for developing different drugs and vaccines including two of the five homegrown Covid-19 vaccines: Mambisa and Abdala.

Abdala, the first coronavirus vaccine conceived in Latin America, proved a 92.28% effectiveness in its Phase III clinical trial. Millions of doses have already been administered in Cuba and other countries such as Venezuela, Nicaragua, the Sahrawi Arab Democratic Republic and Vietnam.

The Mambisa vaccine candidate is among vaccines designed globally to be applied nasally.

CIGB is also working on other topics and technological platforms, including recombinant proteins, chemical synthesis and synthetic peptides.

In an interview with Prensa Latina, Gerardo Guillén, CIGB´s Biomedical Research Director, explained specialists are presently working on different protein printing hosts including yeast, mammalian cells and bacteria. Among CIGB´s most-recognized products is Heberferon, a mixture of alpha and gamma interferons in a single vial with synergistic properties based on its anti-proliferative activity.

pll/rgh/joe

LATEST NEWS
RELATED
name of Prensa Latina

| Text SMS to 8100 with content PL
Receive 4 mesages x 25 cup

© 2016-2021 Prensa Latina
Latin American News Agency

Radio – Publications  – Videos – News by the minute.
All Rigts Reserved.

St. E No 454 , Vedado,  Habana, Cuba.
Phones: (+53) 7 838 3496, (+53) 7 838 3497, (+53) 7 838 3498, (+53) 7 838 3499
Prensa Latina © 2021 .

Web Site developed by IT Division  Prensa Latina.